[go: up one dir, main page]

ES2177579T3 - Solucion acuosa de factor viii de bajo contenido en oxigeno. - Google Patents

Solucion acuosa de factor viii de bajo contenido en oxigeno.

Info

Publication number
ES2177579T3
ES2177579T3 ES94915307T ES94915307T ES2177579T3 ES 2177579 T3 ES2177579 T3 ES 2177579T3 ES 94915307 T ES94915307 T ES 94915307T ES 94915307 T ES94915307 T ES 94915307T ES 2177579 T3 ES2177579 T3 ES 2177579T3
Authority
ES
Spain
Prior art keywords
factor viii
oxygen
activity
water solution
solution contained
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94915307T
Other languages
English (en)
Inventor
Thomas Osterberg
Angelica Fatouros
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Swedish Orphan Biovitrum AB
Original Assignee
Biovitrum AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovitrum AB filed Critical Biovitrum AB
Application granted granted Critical
Publication of ES2177579T3 publication Critical patent/ES2177579T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A UN FARMACO FINAL QUE CONTIENE UN FACTOR DE COAGULACION VIII EN UNA SOLUCION ACUOSA CON UNA CONCENTRACION REDUCIDA DE OXIGENO. DE ESTE MODO, LA ACTIVIDAD DEL FACTOR VIII SE PUEDE RETENER DURANTE SU ALMACENAMIENTO HASTA UN GRADO SORPRENDENTEMENTE ALTO. LA ACTIVIDAD DEL FACTOR VIII SE PUEDE RETENER DURANTE UN PERIODO PROLONGADO DE TIEMPO SI EL FARMACO FINAL CONTIENE ADEMAS UN GAS INERTE Y/O UN ANTIOXIDANTE. LA PRESENTE INVENCION TAMBIEN SE REFIERE A PROCESOS PARA REDUCIR LA CONCENTRACION DE OXIGENO DE LA SOLUCION ACUOSA Y A UN METODO PARA MEJORAR LA ESTABILIDAD DEL FACTOR VIII EN UNA SOLUCION ACUOSA MEDIANTE EL ALMACENAMIENTO DE LA SOLUCION BAJO UNA ATMOSFERA DE GAS INERTE. CON LA PRESENTE INVENCION SE PUEDE RETENER AL MENOS UN 50% DE LA ACTIVIDAD INICIAL DEL FACTOR VIII TRAS EL ALMACENAMIENTO DURANTE AL MENOS 6 MESES A UNA TEMPERATURA DE 2 A 10 (GRADOS) C Y A UN PH DE LA SOLUCION DE 6,5 A 8,5.
ES94915307T 1993-05-07 1994-03-24 Solucion acuosa de factor viii de bajo contenido en oxigeno. Expired - Lifetime ES2177579T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE19939301581A SE9301581D0 (sv) 1993-05-07 1993-05-07 Protein formulation

Publications (1)

Publication Number Publication Date
ES2177579T3 true ES2177579T3 (es) 2002-12-16

Family

ID=20389868

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94915307T Expired - Lifetime ES2177579T3 (es) 1993-05-07 1994-03-24 Solucion acuosa de factor viii de bajo contenido en oxigeno.

Country Status (24)

Country Link
US (1) US5962650A (es)
EP (1) EP0700299B1 (es)
JP (1) JP3751633B2 (es)
KR (1) KR100304143B1 (es)
CN (1) CN1113655C (es)
AT (1) ATE218354T1 (es)
AU (1) AU681883B2 (es)
CA (1) CA2161350C (es)
CZ (1) CZ293527B6 (es)
DE (1) DE69430745T2 (es)
DK (1) DK0700299T3 (es)
EE (1) EE03118B1 (es)
ES (1) ES2177579T3 (es)
FI (1) FI111910B (es)
HU (1) HU215263B (es)
NO (1) NO321769B1 (es)
NZ (1) NZ266031A (es)
PL (1) PL174866B1 (es)
PT (1) PT700299E (es)
RU (1) RU2142290C1 (es)
SE (1) SE9301581D0 (es)
SK (1) SK283002B6 (es)
WO (1) WO1994026286A1 (es)
ZA (1) ZA942251B (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE504074C2 (sv) * 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
IL113010A (en) * 1994-03-31 1999-10-28 Pharmacia & Upjohn Ab Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
SE9403915D0 (sv) * 1994-11-14 1994-11-14 Annelie Almstedt Process A
SE9501189D0 (sv) * 1995-03-31 1995-03-31 Pharmacia Ab Protein formulation
US5929031A (en) * 1995-05-02 1999-07-27 Baxter Biotech Technology Sarl Storage stable hemoglobin solutions
US5925738A (en) * 1995-12-01 1999-07-20 The American National Red Cross Methods of production and use of liquid formulations of plasma proteins
US7560107B2 (en) 1996-06-26 2009-07-14 Emory University Modified factor VIII
US5763401A (en) * 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
CA2634674A1 (en) 1999-02-22 2000-08-24 Baxter International Inc. Novel albumin-free factor viii formulations
DE60024268T2 (de) * 1999-07-13 2006-08-03 Biovitrum Ab Zusammensetzungen mit stabilem faktor viii
JP3466516B2 (ja) 1999-09-07 2003-11-10 科学技術振興事業団 安定保存可能な酸素輸液剤
EP1458408B1 (en) 2001-12-21 2009-04-15 Novo Nordisk Health Care AG Liquid composition of factor vii polypeptides
IL162618A0 (en) * 2001-12-21 2005-11-20 Novo Nordisk As Liquid composition of modified factor vii polypeptides
GB0207092D0 (en) 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
US20040009918A1 (en) * 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
DK2283856T3 (da) * 2002-06-21 2017-11-20 Novo Nordisk Healthcare Ag Stabiliserede, faste sammensætninger af Faktor VIIa-polypeptider
US7897734B2 (en) 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
KR20060015574A (ko) * 2003-05-23 2006-02-17 노보 노르디스크 헬스 케어 악티엔게젤샤프트 용액 중 단백질 안정화
ES2382157T3 (es) * 2003-06-25 2012-06-05 Novo Nordisk Health Care Ag Composición líquida de polipépttidos del factor VII
DE602004023848D1 (de) * 2003-07-01 2009-12-10 Novo Nordisk Healthcare Ag Von factor vii polypeptiden
BRPI0413518A (pt) 2003-08-14 2006-10-10 Novo Nordisk Healthcare Ag composição farmacêutica lìquida aquosa, método para preparar e uso da mesma, método para tratar uma sìndrome responsiva ao fator vii, e, recipiente hermético
ES2676644T3 (es) * 2003-12-19 2018-07-23 Novo Nordisk Health Care Ag Composiciones estabilizadas de polipéptidos de factor VII
DK1750733T3 (da) * 2004-05-03 2014-01-20 Univ Emory FREMGANGSMÅDE TIL INDGIVELSE AF SVINE-B-DOMÆNELØS fVIII
US7504377B2 (en) 2006-10-23 2009-03-17 Ikor, Inc. Nitric oxide-blocked cross-linked tetrameric hemoglobin
US7494974B2 (en) 2006-10-24 2009-02-24 Ikor, Inc. Carboxymethylated cross-linked tetrameric hemoglobin
ES2344719T3 (es) * 2007-04-17 2010-09-03 DR. WILLMAR SCHWABE GMBH & CO. KG Procedimiento para la preparacion de soluciones estables en almacenamiento de extractos de pelargonio.
PL2167526T3 (pl) * 2007-07-11 2011-09-30 Novo Nordisk As Oczyszczanie czynnika VIII za pomocą żywicy o mieszanej funkcji lub wielofunkcyjnej
EP2113564A1 (en) 2008-05-01 2009-11-04 Arecor Limited Protein formulation
MX2011001624A (es) 2008-08-21 2011-03-28 Octapharma Ag Factor viii y ix humano producido en forma recombinante.
RU2510279C3 (ru) * 2008-09-03 2017-04-17 Октафарма Аг Новые защитные композиции для рекомбинантного фактора viii
EP2385825B1 (en) 2008-11-07 2018-10-10 University of Connecticut Factor viii formulations
US10172949B2 (en) 2009-06-09 2019-01-08 Prolong Pharmaceuticals, LLC Hemoglobin compositions
DK2440239T3 (en) * 2009-06-09 2017-10-16 Prolong Pharmaceuticals Llc HEMOGLOBIN FORMATIONS
US10172950B2 (en) 2009-06-09 2019-01-08 Prolong Pharmaceuticals, LLC Hemoglobin compositions
GB0915480D0 (en) * 2009-09-04 2009-10-07 Arecor Ltd Stable formulation of factor viii
US9199016B2 (en) 2009-10-12 2015-12-01 New Health Sciences, Inc. System for extended storage of red blood cells and methods of use
US11284616B2 (en) 2010-05-05 2022-03-29 Hemanext Inc. Irradiation of red blood cells and anaerobic storage
US12089589B2 (en) 2009-10-12 2024-09-17 Hemanext Inc. Irradiation of red blood cells and anaerobic storage
EP2608816B1 (en) 2010-08-25 2023-07-05 Hemanext Inc. Method for enhancing red blood cell quality and survival during storage
EP4218412A1 (en) 2010-11-05 2023-08-02 Hemanext Inc. Irradiation of red blood cells and anaerobic storage
BR112013011041B1 (pt) 2010-11-05 2021-05-25 Baxalta GmbH variante de fator viii, método para produzir uma variante de fviii, uso da variante de fator viii, e, composição farmacêutica
US9067004B2 (en) 2011-03-28 2015-06-30 New Health Sciences, Inc. Method and system for removing oxygen and carbon dioxide during red cell blood processing using an inert carrier gas and manifold assembly
JP6097293B2 (ja) 2011-08-10 2017-03-15 ニュー・ヘルス・サイエンシーズ・インコーポレイテッドＮｅｗ Ｈｅａｌｔｈ Ｓｃｉｅｎｃｅｓ， Ｉｎｃ． 一体型の白血球、酸素及び／又は二酸化炭素減損・血漿分離フィルタ装置
CA3205441A1 (en) 2013-02-28 2014-09-04 Hemanext Inc. Gas depletion and gas addition devices for blood treatment
ES2524516B1 (es) * 2014-05-29 2015-03-31 Grifols Worldwide Operations Limited Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido
ES2902499T3 (es) 2015-03-10 2022-03-28 Hemanext Inc Kits desechables de reducción de oxígeno, dispositivos y procedimientos de uso de los mismos
JP7175611B2 (ja) 2015-04-23 2022-11-21 ヘマネクスト インコーポレイテッド 嫌気性血液保存容器
JP7075215B2 (ja) 2015-05-18 2022-05-25 ヘマネクスト インコーポレイテッド 全血の保存のための方法および全血の組成
KR20240132129A (ko) 2016-05-27 2024-09-02 헤마넥스트 인코포레이티드 혐기성 혈액 저장 및 병원체 불활성화 방법
EP3833382A1 (en) 2018-08-07 2021-06-16 GlaxoSmithKline Biologicals S.A. Processes and vaccines

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2896381A (en) * 1954-05-27 1959-07-28 Hodes Lange Corp Method and apparatus for treating and filling ampoules
US3143471A (en) * 1962-01-18 1964-08-04 Merck & Co Inc Argon method of drying and preserving lyophilized therapeutic products
US4165370A (en) * 1976-05-21 1979-08-21 Coval M L Injectable gamma globulin
US4783441A (en) * 1979-04-30 1988-11-08 Hoechst Aktiengesellschaft Aqueous protein solutions stable to denaturation
DE3144705C2 (de) * 1981-11-11 1983-12-08 Biotest-Serum-Institut Gmbh, 6000 Frankfurt Verfahren zur Herstellung eines lagerstabilen, vernetzten Hämoglobinpräparates mit hoher Sauerstoff-Transportkapazität, sowie das nach diesem Verfahren hergestellte Hämoglobinpräparat
US4481189A (en) * 1982-04-14 1984-11-06 New York Blood Center Inc. Process for preparing sterilized plasma and plasma derivatives
US4727027A (en) * 1983-05-02 1988-02-23 Diamond Scientific Co. Photochemical decontamination treatment of whole blood or blood components
US4597966A (en) * 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
DE3577801D1 (de) * 1985-08-05 1990-06-28 Immuno Ag Verfahren zur herstellung von praeparationen auf basis von blutgerinnungsfaktoren.
US4709819A (en) * 1986-07-23 1987-12-01 Environmental Diagnostics, Inc. Method for preserving plated media and product
CA1292686C (en) * 1986-10-27 1991-12-03 Ze'ev Shaked Pharmaceutical compositions of recombinant interleukin-2 and formulation process
CA1329760C (en) * 1987-10-29 1994-05-24 Ted C. K. Lee Plasma and recombinant protein formulations in high ionic strength media
US4877608A (en) * 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
GB8808810D0 (en) * 1988-04-14 1988-05-18 Biopharm Clinical Research Ltd Heparin-containing formulations
FR2630115B1 (fr) * 1988-04-14 1994-10-28 Merieux Inst Procede de stabilisation des solutions d'albumine humaine et solution obtenue
US5096885A (en) * 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
SE465222C5 (sv) * 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
DE4001451A1 (de) * 1990-01-19 1991-08-01 Octapharma Ag Stabile injizierbare loesungen von faktor viii und faktor ix
DE4111393A1 (de) * 1991-04-09 1992-10-15 Behringwerke Ag Stabilisierte faktor viii-praeparationen
DE69528076T2 (de) * 1994-10-31 2003-04-30 Kimberly-Clark Worldwide, Inc. Hochdichte faservliesfiltermedien

Also Published As

Publication number Publication date
SE9301581D0 (sv) 1993-05-07
ZA942251B (en) 1994-11-01
SK138395A3 (en) 1997-02-05
KR100304143B1 (ko) 2001-11-22
CN1122573A (zh) 1996-05-15
WO1994026286A1 (en) 1994-11-24
PT700299E (pt) 2002-11-29
CN1113655C (zh) 2003-07-09
HUT73693A (en) 1996-09-30
SK283002B6 (sk) 2003-01-09
RU2142290C1 (ru) 1999-12-10
NO954457D0 (no) 1995-11-07
FI111910B (fi) 2003-10-15
CA2161350C (en) 2007-10-30
JPH08509745A (ja) 1996-10-15
HU215263B (hu) 1998-11-30
DE69430745D1 (de) 2002-07-11
EP0700299B1 (en) 2002-06-05
PL311567A1 (en) 1996-02-19
FI955305A (fi) 1995-11-06
HU9503171D0 (en) 1996-01-29
PL174866B1 (pl) 1998-09-30
NO321769B1 (no) 2006-07-03
FI955305A0 (fi) 1995-11-06
EP0700299A1 (en) 1996-03-13
AU681883B2 (en) 1997-09-11
CA2161350A1 (en) 1994-11-24
CZ286995A3 (en) 1996-05-15
US5962650A (en) 1999-10-05
JP3751633B2 (ja) 2006-03-01
NO954457L (no) 1995-11-07
CZ293527B6 (cs) 2004-05-12
DK0700299T3 (da) 2002-09-23
ATE218354T1 (de) 2002-06-15
NZ266031A (en) 1997-04-24
EE03118B1 (et) 1998-10-15
DE69430745T2 (de) 2002-10-17
KR960702317A (ko) 1996-04-27
AU6659794A (en) 1994-12-12

Similar Documents

Publication Publication Date Title
ES2177579T3 (es) Solucion acuosa de factor viii de bajo contenido en oxigeno.
JPS6490123A (en) Nitroglycerol spray agent
SG46496A1 (en) Tricyclopolyazamacrocyclophosphonic acids complexes and derivatives thereof for use as constrast agents
DE69734605D1 (de) Abgeschwächter salmonellenstamm, gebraucht als vehikel zur oralen immunisierung
ATE151620T1 (de) Gefässimplantat
ATE280150T1 (de) Verfahren zur herstellung von mono-langkettigen aminoxid tensiden mit niedrigem nitrit-, nitrosamin- und restperoxid-gehalt
ATE161174T1 (de) Feste zubereitung mit hoher freisetzung, ihre herstellung und verwendung
ES2071292T3 (es) Soluciones inyectables estables de factor viii.
AU3369299A (en) Stable concentrated rare earth carboxylate liquids
DE69630291D1 (de) Proteinformulierung, die koajulationsfehler viii oder ix in einer saccharose wässriger lösung enthält
BR0213298A (pt) formulações com alta concentração de proteìna e processo de fabricação
Katz Anhydrous hydrogen fluoride as a solvent for proteins and some other biologically important substances
KR950005986A (ko) 안정화된 형태로 금속 프로테아제 효소를 사용, 저장 및 이송하는 방법
ATE221919T1 (de) In flüssiger form stabiler thiolaktivator
GB1476883A (en) Oxygenation of water
SE9402119D0 (sv) Solution
JPS57128635A (en) Pharmaceutical preparation of gamma-globulin for venoclysis
ATE451109T1 (de) Medizinische lösung; verfahren zur herstellung dieser lösung und ihre verwendung
JPS6463342A (en) Stabilization of glutathione-containing composition
TW332199B (en) Process for the preparation of 3-chloropropionic acid
DE59400836D1 (de) Flüssiggasformulierung zur Vitalitätsprüfung von Zähnen
MX9606271A (es) Composiciones generadoras de gas que contienen acido d,1-tartarico.
UA30501A (uk) Спосіб лікування склеродермії у дітей з утягненням в патологічний процес органів шлунково-кишкового тракту
FI891595A (fi) Menetelmä hajusteen lisäämiseksi happikaasuun